A 28-year-old man with relapsed classical Hodgkin lymphoma is started on brentuximab vedotin. The basis of its tumour selectivity is:
- A Binding CD30 on Reed-Sternberg cells with release of monomethyl auristatin E inside the cell ✓
- B Blocking the CD30 ligand and preventing JAK-STAT survival signalling
- C Delivering doxorubicin selectively via a liposomal carrier taken up by CD30-positive cells
- D Recruiting T cells to CD30-positive cells through a bispecific linker
Correct answer: A. Binding CD30 on Reed-Sternberg cells with release of monomethyl auristatin E inside the cell
Explanation
Brentuximab vedotin is an antibody-drug conjugate: an anti-CD30 antibody linked to monomethyl auristatin E, a microtubule-disrupting agent. After binding CD30 on Reed-Sternberg cells the complex is internalised and the payload is released lysosomally, giving selectivity over free drug. It does not block CD30 signalling, carry doxorubicin, or act as a bispecific engager.
Reference: Katzung's Basic and Clinical Pharmacology, 16th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.